288 related articles for article (PubMed ID: 28617447)
1. Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.
Liu K; Zhang X; Xu W; Chen J; Yu J; Gamble JR; McCaughan GW
Clin Transl Gastroenterol; 2017 Jun; 8(6):e98. PubMed ID: 28617447
[TBL] [Abstract][Full Text] [Related]
2. Batimastat nanoparticles associated with transcatheter arterial chemoembolization decrease hepatocellular carcinoma recurrence.
Xiao L; Wang M
Cell Biochem Biophys; 2014 Sep; 70(1):269-72. PubMed ID: 24639109
[TBL] [Abstract][Full Text] [Related]
3. TACE versus TAE as therapy for hepatocellular carcinoma.
Pleguezuelo M; Marelli L; Misseri M; Germani G; Calvaruso V; Xiruochakis E; Manousou P; Burroughs AK
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1623-41. PubMed ID: 18925854
[TBL] [Abstract][Full Text] [Related]
4. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake.
Matuszewska K; Pereira M; Petrik D; Lawler J; Petrik J
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503254
[TBL] [Abstract][Full Text] [Related]
5. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
7. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
Kim DY; Han KH
Dig Dis; 2012; 30(6):598-602. PubMed ID: 23258101
[TBL] [Abstract][Full Text] [Related]
8. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
Sangro B
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
[TBL] [Abstract][Full Text] [Related]
9. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma.
Mossenta M; Busato D; Baboci L; Cintio FD; Toffoli G; Bo MD
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370258
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
11. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
12. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
13. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
14. Chemoembolization for hepatocellular carcinoma.
Lencioni R
Semin Oncol; 2012 Aug; 39(4):503-9. PubMed ID: 22846867
[TBL] [Abstract][Full Text] [Related]
15. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
16. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
Qian J; Oppermann E; Tran A; Imlau U; Qian K; Vogl TJ
World J Gastroenterol; 2016 Jun; 22(21):5042-9. PubMed ID: 27275096
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.
Cheng AL; Amarapurkar D; Chao Y; Chen PJ; Geschwind JF; Goh KL; Han KH; Kudo M; Lee HC; Lee RC; Lesmana LA; Lim HY; Paik SW; Poon RT; Tan CK; Tanwandee T; Teng G; Park JW
Liver Int; 2014 Feb; 34(2):174-83. PubMed ID: 24251922
[TBL] [Abstract][Full Text] [Related]
18. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.
Sciarra A; Ronot M; Di Tommaso L; Raschioni C; Castera L; Belghiti J; Bedossa P; Vilgrain V; Roncalli M; Paradis V
Liver Int; 2015 Nov; 35(11):2466-73. PubMed ID: 25865109
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.
Yoo JJ; Lee JH; Lee SH; Lee M; Lee DH; Cho Y; Lee YB; Yu SJ; Kim HC; Kim YJ; Yoon JH; Kim CY; Lee HS
PLoS One; 2014; 9(11):e113926. PubMed ID: 25427152
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
